Merck KGaA (MKGAF) News Today → Why Is Gold On a MASSIVE rally? (From Huge Alerts) (Ad) Free MKGAF Stock Alerts $180.00 -2.50 (-1.37%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 10:50 AM | businesswire.comAulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007May 15 at 10:48 AM | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Short Interest Up 23.8% in AprilMerck KGaA (OTCMKTS:MKGAF - Get Free Report) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 682,700 shares, a growth of 23.8% from the April 15th total of 551,400 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is presently 1,706.8 days.May 15 at 1:30 AM | reuters.comMerck KGaA's Q1 adjusted profit declines less than fearedMay 9, 2024 | msn.comMerck says Keytruda failed as first-line therapy for uterine cancerApril 29, 2024 | finance.yahoo.comMerck KGaA's Dividend AnalysisApril 28, 2024 | finance.yahoo.comMerck KGaA (ETR:MRK) Is Due To Pay A Dividend Of €2.20April 20, 2024 | finance.yahoo.comShareholders Will Most Likely Find Merck KGaA's (ETR:MRK) CEO Compensation AcceptableApril 15, 2024 | finance.yahoo.comMerck KGaA's (ETR:MRK) investors will be pleased with their favorable 74% return over the last five yearsApril 4, 2024 | msn.comMerck to test lung cancer combo therapy in late-stage trialMarch 29, 2024 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Stock Passes Above 50 Day Moving Average of $168.61Merck KGaA (OTCMKTS:MKGAF) Shares Cross Above 50-Day Moving Average of $168.61March 28, 2024 | msn.comMerck Drug for Rare Form of High Blood Pressure Gets US NodMarch 27, 2024 | benzinga.comMerck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung DiseaseMarch 27, 2024 | msn.comMerck hits all-time high after FDA nod for lung disease therapyMarch 16, 2024 | seekingalpha.comMerck KGaA: Moving To A Hold As 2025 Targets Are Now DoubtfulMarch 12, 2024 | finance.yahoo.comMerck KGaA Full Year 2023 Earnings: In Line With ExpectationsMarch 7, 2024 | reuters.comMerck KGaA forecasts return to organic earnings growth in 2024February 20, 2024 | msn.comFDA accepts Merck's Keytruda application for priority reviewFebruary 16, 2024 | finance.yahoo.comMerck KGaA (MKGAF) Stock Historical Prices & Data - Yahoo FinanceFebruary 1, 2024 | msn.comMerck Stock Jumps as Earnings Beat, Guidance Ahead of Wall Street ExpectationsFebruary 1, 2024 | msn.comMerck Cancer Drug Keytruda Drives Sales Past Street EstimatesAugust 3, 2023 | msn.comMerck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023July 25, 2023 | finance.yahoo.comData Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing AgreementJuly 14, 2023 | msn.comMaravai LifeSciences gains on report of takeover interest from Germany's MerckJune 22, 2023 | finance.yahoo.comChina’s Chesir Eyes Merck KGaA’s €1 Billion Pigments ArmNovember 21, 2022 | finance.yahoo.comMerck KGaA in push to become twice as productive in drug developmentNovember 10, 2022 | seekingalpha.comMERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q3 2022 Results - Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comMerck KGaA's earnings beat consensus on lab equipment, drug salesOctober 22, 2022 | fool.comMERCK KGAA DM 5 (OTC: MKGAF)October 6, 2022 | finance.yahoo.comMerck KGaA says larger-scale acquisitions an option from 2023September 27, 2022 | finanznachrichten.deMerck: KEYTRUDA Approved In Canada For Adjuvant Treatment Of Patients With Stage IIB Or IIC MelanomaSeptember 19, 2022 | marketbeat.comJefferies Financial Group Brokers Lift Earnings Estimates for MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF)MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF - Get Rating) - Equities researchers at Jefferies Financial Group lifted their FY2024 earnings per share estimates for shares of MERCK Kommanditgesellschaft auf Aktien in a report released on Thursday, September 15th. Jefferies Financial GroupJuly 27, 2022 | marketbeat.comBrokers Set Expectations for MERCK Kommanditgesellschaft auf Aktien's Q2 2022 Earnings (OTCMKTS:MKGAF)MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF - Get Rating) - Stock analysts at Jefferies Financial Group issued their Q2 2022 EPS estimates for shares of MERCK Kommanditgesellschaft auf Aktien in a research report issued on Monday, July 25th. Jefferies Financial Group analyst P. WelfordJuly 13, 2022 | finance.yahoo.comMicron to Select Athinia™ for Pioneering Data CollaborationMay 14, 2022 | markets.businessinsider.comDGAP-DD: Merck KGaA englishMay 12, 2022 | seekingalpha.comMERCK Kommanditgesellschaft auf Aktien Non-GAAP EPS of €2.41, revenue of €5.2B; updates FY22 guidance Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKGAF and its competitors with MarketBeat's FREE daily newsletter. Email Address The Presidential candidate you should REALLY be worried about (Ad)The Presidential candidate you should REALLY be worried about Most Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started. Get the full story right here. MKGAF Media Mentions By Week MKGAF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKGAF News Sentiment▼-0.210.53▲Average Medical News Sentiment MKGAF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKGAF Articles This Week▼40▲MKGAF Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKGAF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alnylam Pharmaceuticals News Genmab A/S News Astellas Pharma News BioMarin Pharmaceutical News Teva Pharmaceutical Industries News BeiGene News Viatris News Sarepta Therapeutics News Dr. Reddy's Laboratories News United Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKGAF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchShocking $16T Elon Musk Crypto LeakCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
